A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-13

Study Completion Date

2009-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

NCT00424697

Healthy Subjects

COMPLETED PHASE1

fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

NCT00332046

Social Anxiety Disorder

COMPLETED PHASE1

Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis

NCT04004416

Schizophrenia Bipolar Disorder Healthy +4 more

COMPLETED PHASE4

Treating Emotional Processing Impairments in Individuals With TBI

NCT03373331

Traumatic Brain Injury

UNKNOWN NA

Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders

NCT00097175

Depressive Disorder, Major

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder and Anxiety Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

placebo arm

There are single dose treatment arms of GSK561679, lorazepam as well as placebo.

Group Type PLACEBO_COMPARATOR

single dose

Intervention Type DRUG

Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.

GSK561679 arm

There are single dose treatment arms of GSK561679, lorazepam as well as placebo.

Group Type EXPERIMENTAL

single dose

Intervention Type DRUG

Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.

lorazepam arm

There are single dose treatment arms of GSK561679, lorazepam as well as placebo.

Group Type ACTIVE_COMPARATOR

single dose

Intervention Type DRUG

Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

single dose

Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males
* Non-smokers
* Body weight 50 kg (110 lbs) or higher, and BMI within the range 19-29.9 kg/m2
* Normal ECG.

Exclusion Criteria

* Any serious medical disorder or condition.
* Any history of an endocrine disorder.
* Any clinically significant laboratory abnormality.
* History of psychiatric illness.
* Any history of suicidal attempts or behavior.
* History or current diagnosis of acute narrow angle glaucoma.
* Left handed

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes